Obese adolescents exhibit a constant ratio of GH isoforms after whole body vibration and maximal voluntary contractions by A.E. Rigamonti et al.
Rigamonti et al. BMC Endocrine Disorders           (2018) 18:96 
https://doi.org/10.1186/s12902-018-0323-6RESEARCH ARTICLE Open AccessObese adolescents exhibit a constant ratio
of GH isoforms after whole body vibration
and maximal voluntary contractions
A. E. Rigamonti1*, M. Haenelt2, M. Bidlingmaier2, A. De Col3, S. Tamini3, G. Tringali3, R. De Micheli3, L. Abbruzzese3,4,
C. R. Goncalves da Cruz5,6, M. Bernardo-Filho5, S. G. Cella1 and A. Sartorio3,4Abstract
Background: Growth hormone (GH) is a heterogeneous protein composed of several molecular isoforms, the most
abundant ones being the 22 kDa- and 20 kDa-GH. Exercise-induced secretion of GH isoforms has been extensively
investigated in normal-weight individuals due to antidoping purposes, particularly recombinant human GH (rhGH)
abuse. On the other hand, the evaluation of exercise-induced responses in GH isoforms has never been performed
in obese subjects.
Methods: The acute effects of whole body vibration (WBV) or maximal voluntary contraction (MVC) alone and the
combination of MVC with WBV (MVC +WBV) on circulating levels of 22 kDa- and 20 kDa-GH were evaluated in 8
obese male adolescents [mean age ± SD: 17.1 ± 3.3 yrs.; weight: 107.4 ± 17.8 kg; body mass index (BMI): 36.5 ± 6.6 kg/m2;
BMI standard deviation score (SDS): 3.1 ± 0.6].
Results: MVC (alone or combined with WBV) significantly stimulated 22 kDa- and 20 kDa-GH secretion, while WBV alone
was ineffective. In particular, 22 kDa- and 20 kDa-GH peaks were significantly higher after MVC +WBV and MVC than
WBV. In addition, 22 kDa-GH (but not 20 kDa-GH) peak was significantly higher after MVC +WBV than MVC. Importantly,
the ratio of circulating levels of 22 kDa- to 20 kDa-GH was constant throughout the time window of evaluation after
exercise and similar among the three different protocols of exercise.
Conclusions: The results of the present study confirm the ability of MVC, alone and in combination with WBV, to
stimulate both 22 kDa- and 20 kDa-GH secretion in obese patients, these responses being related to the exercise
workload. Since the ratio of 22 kDa- to 20 kDa-GH is constant after exercise and independent from the protocols of
exercise as in normal-weight subjects, hyposomatotropism in obesity does not seem to depend on an unbalance of
circulating GH isoforms. Since the present study was carried out in a small cohort of obese sedentary adolescents,
these preliminary results should be confirmed in further future studies enrolling overweight/obese subjects with a
wider age range.
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Pituitary and circulating growth hormone (GH) is a hetero-
geneous mix of molecules deriving from different gene ex-
pression, alternative splicing, post-translational modifications,
homo- or hetero-dimerization and oligomerization, periph-
eral metabolism and clearance. The predominant iso-
form is the 1- to 191-amino acid 22 kDa-GH, while
alternative splicing of the exon 3 removes the residues
32–46 from the primary structure, yielding the 176-amino
acid 20 kDa-GH, which represents about 15–20% of total
circulating GH [1, 2].
In the last decade. Analytical methods have been im-
plemented to measure circulating levels of GH isoforms
with adequate accuracy, specificity and sensitivity [3].
Since the biochemical heterogeneity of GH implies a dif-
ferent binding of the ligand to the receptor, dimerization
of GH receptor, receptor activation and signal transduc-
tion [2], measurement of GH isoforms is fundamental to
understand the complexity of the physiological effects of
GH or, more appropriately, “somatotropic hormones”.
Exercise-induced GH secretion has been extensively
investigated in the last decades, several factors being
identified to affect this response, including duration, in-
tensity and protocol of exercise, training, nutritional sta-
tus, body composition, age and gender of individuals
undergoing exercise and concomitant pathophysiological
conditions, such as GH deficiency (GHD) [4].
In this context, morbid obesity is characterized by hypo-
somatotropism, which is associated with blunted GH re-
sponses to a variety of pharmacological and physiological
stimuli, including exercise [5, 6].
The interest of measuring circulating levels of GH
isoforms after exercise has derived from the need to val-
idate a promising antidoping test, based on the altered
ratio of circulating GH isoforms in athletes administered
with recombinant human GH (rhGH), which corresponds
uniquely to 22 kDa-GH [7–9].
Some studies, carried out in normal-weight subjects,
have revealed a post-exercise increase in circulating levels
of GH isoforms, mainly 22 kDa- and 20 kDa-GH, being
those of non-22 kDa-GH isoforms more sustained in the
recovery phase, presumably for their long half-life [10–14].
Since non-22 kDa-GH isoforms are more hyperglycemic
than 22 kDa-GH [15], the subject should be protected by
post-exercise hypoglycaemia.
Surprisingly, to the best of our knowledge, no one
has ever evaluated exercise-induced release of GH
isoforms in obese subjects. Therefore, aim of the
present study was to measure circulating levels of 22
kDa-GH and 20 kDa-GH in a cohort of obese subjects
undergoing different protocols of exercise at increas-
ing intensity (i.e. whole body vibration (WBV) and
maximal voluntary contractions (MVC)]. For our ex-
perience, these types of exercise have demonstratedto be capable to stimulate “total” GH secretion in
either normal-weight or obese subjects [16–20].
Methods
Since the present study represents the development of a
previous research performed in healthy normal-weight
and obese subjects by our group, the methodology widely
replicates that adopted in the previous papers [16, 18].
Subjects
Eight obese male adolescents [mean age ± SD: 17.1 ± 3.3
years; weight: 107.4 ± 17.8 kg; body mass index (BMI):
36.5 ± 6.6 kg/m2; BMI standard deviation score (SDS):
3.1 ± 0.6; waist circumference: 118.3 ± 18.0 cm; hip circum-
ference: 123.9 ± 15.3 cm] were recruited among patients
hospitalized for a multidisciplinary integrated body weight
reduction program at the Division of Auxology, Istituto
Auxologico Italiano, Piancavallo (VB), Italy. In order to
avoid any carry-over effect of the weight loss or modifica-
tions in diet and physical activity on GH secretion, the entire
study was completed before starting the multidisciplinary
integrated body weight reduction program.
All the adolescent patients voluntarily participated in
this investigation after obtaining a written informed con-
sent given by their parents. The main criteria of exclu-
sion were any overt disease apart from morbid obesity.
Diabetes mellitus, including glucose intolerance, was ex-
cluded by a 75 g oral glucose load, while Prader-Willi
syndrome was excluded by clinical history, physical
examination and FISH detection of chromosome 15
deletions. Due to the effects of female sex steroids on
GH secretion and the difficulty to perform three exercise
protocols (see below) in the same phase of the menstrual
cycle, only boys were included in the study. Thyroidal
(TSH and free T4 levels) and gonadal functions (LH,
FSH, testosterone levels) were normal in all subjects
(data not shown). All of them were habitually sedentary
and were not involved in any strength or endurance
training in the previous 2 weeks preceding the admission
to the study protocol. No subjects had any signs of
musculoskeletal disorders potentially hampering the exe-
cution of the tests.
No drugs or nutritional supplements known to inter-
fere with GH and/or cortisol secretion were taken by the
subjects in the month preceding the study.
Testing
After an overnight fast, subjects were admitted to the
laboratory 1 h before the beginning of the tests.
All the participants performed one of the following
exercise protocols per diem: WBV alone, MVC alone,
and MVC alternated with WBV (MVC +WBV).
The three different exercise protocols were randomly car-
ried out in separate days with an interval of at least two days
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generated by the web-site https://www.randomizer.org.
After a 5-min standardized warm-up on a cycloerg-
ometer (power: 50W, cadence: 60 rpm), the three differ-
ent protocols were performed as reported in Fig. 1.
During the WBV protocol, subjects initially seated in a
semi-recumbent position on a horizontal leg press ma-
chine (Technogym, Gambettola, Italy) for 30 s, with the
trunk-thigh and thigh-shank angles at 80°, without produ-
cing any movement. This first step was then followed by a
30-s WBV bout administered while the subject stood on a
vibrating platform (Nevisys H1©, RME, Ferrara, Italy), as
previously described [16]. Vertical sinusoidal vibrations
were generated at a frequency of 35Hz, the acceleration
of the platform being 2.85 g at a peak-to-peak amplitude
of vibration of 5 mm. These two rest-WBV cycles were re-
peated 15 times, resulting in a total duration of 15min.
During the MVC protocol, subjects were initially placed
on the leg press machine in the same supine position as
described in the WBV protocol. The subjects performed
three 5-s MVC, separated by 5-s resting periods in be-
tween. This first step was then followed by a 30 s of rest in
the same static position as in the WBV protocol, but with-
out WBV. These two MVC-rest cycles were repeated 15
times, resulting in a total duration of 15min.
During the MVC +WBV protocol, subjects initially
performed the three 5-s MVC (separated by 5-s resting
periods in between) as in the MVC protocol. This first
step was then followed by a 30-s WBV bout as in the
WBV protocol. These two MVC +WBV cycles were re-
peated 15 times, resulting in a total duration of 15 min.
The characteristics of the different protocols, including
the temporal patterns, are identical to those adopted in
a previous work performed by our group [18] in healthy
normal-weight subjects.
Blood sampling and measurements of GH isoforms
Blood samples (5ml at each time point) for measurement
of 22 kDa- and 20 kDa-GH levels were drawn before theFig. 1 Schemes of protocols used in the study: whole body vibration only
maximal voluntary contractions and whole body vibration (MCV +WBV). Sestart of the experiment (baseline), immediately at the end
of the exercise (T0) and after 15 (T15), 30 (T30), 45 (T45)
and 75min (T75). All blood samples were drawn through
an indwelling cannula inserted into an ante-cubital vein
kept patent via a continuous infusion of isotonic saline.
All blood samples were allowed to clot, centrifuged for 5
min and immediately stored at − 20 °C for the next analysis.
Serum levels of 22 kDa-GH were measured using the au-
tomated IDS iSYS hGH chemiluminescence assay system.
In this assay, the detection monoclonal antibody (mAb)
targets an epitope in the loop connecting helix 1 and 2 of
GH, which is missing in 20 kDa-GH, thereby conferring
specificity of the assay for the 22kD-GH molecules. Further
details concerning the methodology had been published in
a previous work [21]. In our hands, functional sensitivity of
the assay was 0.04 μg/L and intra- and inter-assay coeffi-
cients of variation (CVs) both were below 5%.
Serum levels of 20 kDa-GH were measured using an
in-house time resolved fluorescence assay as described
before [22]. The assay employs two mAbs with no
cross-reactivity to 22-kDa GH; intra- and inter-assay
CVs were 5.4 and 6.3% at 0.2 μg/L and the functional
sensitivity was 0.025 μg/L.
All samples were run in the same assay to minimize
inter-assay variability (for both GH isoforms). Some
samples fell below the limits of detection of 20
kDa-GH assay and were excluded from statistical
analysis.
Statistical analyses
The Sigma Stat 3.5 statistical software package was used
for data analyses. GraphPad Prisma 5.0 software was
used for plotting data.
In order to determine a priori the sample size, a power
analysis was performed by considering a difference in
the mean 22 kDa-GH levels at T0 between MVC +WVB
and WBV equal to 2.5 ± 2.5 μg/L with an α error of 0.05
at two tails and a power of 0.80. The result of this calcu-
lation was n = 8 patients.(WBV), maximal voluntary contractions only (MVC) and combination of
e the text for further details
Fig. 2 Circulating levels of 22 kDa- (top panel) and 20 kDa-GH (bottom
panel) after the three different protocols of exercise: maximal voluntary
contractions + whole body vibration (MVC+WBV), muscle voluntary
contractions (MVC) and whole body vibration (WBV). Evaluation was
performed at resting after the completion of the exercise. Values are
expressed as mean ± SD. *p < 0.05 vs. the corresponding basal value
(T0); op < 0.05 vs. the corresponding time point of WBV; ●p < 0.05 vs.
the corresponding time point of MVC
Fig. 3 Ratio of circulating levels of 22 kDa-GH to 20 kDa-GH after the
three different protocols of exercise: maximal voluntary contractions +
whole body vibration (MVC +WBV), muscle voluntary contractions (MVC)
and whole body vibration (WBV). Evaluation was performed at resting
after the completion of the exercise. Values are expressed as mean ± SD
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normally distributed.
Results are reported as mean ± SD (standard devi-
ation). The responses in 22 kDa- and 20 kDa-GH were
evaluated as absolute values for each experimental group
(MVC +WBV, MVC and WBV). Peak values of GH iso-
forms represent the maximal levels reached during each
experimental session.
Circulating levels of 22 kDa- and 20 kDa-GH and the re-
lated ratio (i.e., 22 kDa-GH/20 kDa-GH) were compared
within each experimental group (vs. the corresponding
basal value for MVC+WBV, MVC or WBV) over sam-
pling times (intra-group analysis) and among the three
experimental groups (MVC+WBV vs. MVC or WBV and
MVC vs. WBV) for any sampling time (inter-group ana-
lysis) by using two-way ANOVA with repeated measures
(with the two factors time and group and the interaction
time × group), followed by the post hoc Bonferroni’s test.
One-way ANOVA, followed by the post hoc Bonferroni’s
test, was used to compare 22 kDa- and 20 kDa-GH peaks
and the related ratio (i.e., 22 kDa-GH-peak/20 kDa-GH--
peak) among MVC+WBV, MVC and WBV groups.
A level of significance of p < 0.05 was used for all data
analyses.
Results
Mean basal circulating levels of 22 kDa- and 20
kDa-GH were 1.03 ± 1.52 μg/L and 0.269 ± 0.294 μg/L
before MVC+WBV, 0.97 ± 1.15 μg/L and 0.234 ± 0.209 μg/L
before MVC and 0.91 ± 1.05 μg/L and 0.212 ± 0.195 μg/L
before WBV, respectively, without any significant difference
(Fig. 2). The ratio of circulating levels of 22 kDa- to 20
kDa-GH at 0min was similar among the three protocols
of exercise (basal values: 7.382 ± 4.587 for MCV+WBV,
8.02 ± 4.73 for MCV and 8.31 ± 4.34, respectively) (Fig. 3).
MVC +WBV and MCV evoked a significant in-
crease in 22 kDa-GH levels in obese patients at 0 and
15 min and only at 0 min vs. basal level, respectively
(p < 0.05). WBV was ineffective to stimulate any 22
kDa-GH secretion. The 22 kDa-GH response was signifi-
cantly higher after MVC +WBV than MVC at 0min or
WBV at 0 and 15min and after MVC than WBV at 0min
(p < 0.05) (Fig. 2).
Similarly, MVC +WBV and MCV evoked a signifi-
cant increase in 20 kDa-GH levels at 0 min vs. basal
level (p < 0.05), without any significant changes after
WBV. This response was significantly higher after MVC+
WBV than MVC at 0min or WBV at 0 and 15min and
after MVC than WBV at 0min (p < 0.05) (Fig. 2).
GH peaks after MVC +WBV (22 kDa-GH: 9.72 ±
5.55 μg/L and 20 kDa-GH: 0.98 ± 0.55 μg/L) and after
MVC (22 kDa-GH: 6.45 ± 6.35 μg/L and 20 kDa-GH:
0.72 ± 0.68 μg/L) were significantly higher than those
observed after WBV (22 kDa-GH: 2.27 ± 2.26 μg/L and
Rigamonti et al. BMC Endocrine Disorders           (2018) 18:96 Page 5 of 720 kDa-GH: 0.24 ± 0.25 μg/L) (p < 0.05), being only 22
kDa-GH peak after MVC +WBV higher than that
after MCV (p < 0.05) (Fig. 4).
Importantly, the ratio of circulating levels of 22 kDa- to
20 kDa-GH in obese patients remained constant through-
out the time window of evaluation and paralleled among
the three protocols of exercises (Fig. 3). No significant dif-
ferences were found in the ratio of peak levels of 22 kDa- to
20 kDa-GH among the three protocols of exercise (Fig. 4).
Discussion
The most important findings of the present study carried
out in a cohort of obese adolescents, generally more re-
sponsive to pharmacological or physiological GH stimuli
than obese adults, were: (1) circulating levels of 22 kDa-
and 20 kDa-GH are increased after acute exercise; (2) 22
kDa-GH is quantitatively the main isoform secreted in
circulation after exercise; (3) combination of WBV with
MVC evokes the highest responses in both GH isoforms;
(4) the ratio of circulating levels of 22 kDa- to 20 kDa-GH
is constant throughout the time window of evaluation
after exercise and is similar among three different proto-
cols of exercise (MVC+WBV, MVC and WBV).
Reportedly, the pathophysiology of hyposomatropism
in obese subjects is complex, being presumably multifac-
torial. In particular, central (such as reduced GHRH
function and/or increased somatostatin tone at the
hypothalamic level) and peripheral (such as increased
circulating levels of free fat acids, FFA) mechanisms have
been invoked to explain the blunted GH responses to a
variety of pharmacological and physiological stimuli in this
special population [23–26]. Some authors have (errone-
ously) hypothesized the existence of altered proportions of
GH isoforms in syndromic obesity (e.g., Prader-Willi
syndrome) [27]. Now, we can exclude this possibility alsoFig. 4 Peak values of 22 kDa- and 20 kDa-GH and the related ratio
(i.e., 22 kDa-GH-peak/20 kDa-GH-peak) after the three different
protocols of exercise: maximal voluntary contractions + whole body
vibration (MVC +WBV), muscle voluntary contractions (MVC) and
whole body vibration (WBV). Values are expressed as mean ± SD.
*p < 0.05 vs. WBV; op < 0.05 vs. MVCin morbid obesity, being this the first study evaluating
exercise-induced secretion of GH isoforms in an obese
population and demonstrating a ratio of circulating levels
of 22 kDa- to 20 kDa-GH similar to that of normal-weight
individuals (i.e., about 10–15) [28]. Therefore, hyposoma-
totropism in morbid obesity does not derive from an
alteration in the molecular mechanisms underlying the
generation of GH isoforms, but seems to be a conse-
quence of an insufficient stimulation and/or excessive in-
hibition of GH function (at hypothalamic and/or pituitary
level). Obese state causes a “quantitative” rather than a
“qualitative” alteration of GH secretion.
As shown in the present study, different protocols of
exercise not surprisingly evoked responses in GH iso-
forms that were higher when the workload was heavier,
such as that of MVC +WBV. This finding means not
only the preservation of a “adequate” GH responsiveness
to increasing physiological stimuli in obese subjects, but
also the maintenance of a constant ratio of circulating levels
of 22 kDa- to 20 kDa-GH independently from intensity,
duration and protocol of exercise in both normal-weight
and obese individuals.
In this context, the reliability of the antidoping test,
used to detect rhGH abuse and based on an unbalance
of circulating GH isoforms (particularly, the ratio of 22
kDa- tp pituitary GH, i.e. rGH/pitGH) after rhGH ad-
ministration, would be ensured also in athletes, who, in
some sport disciplines, are frequently overweight or
obese [7, 9, 29]. In fact, as specified above the hyposo-
matotropism, acute exercise and execution of different
protocols of exercise do not change the proportions of
GH isoforms, which are similar to those present in
normal-weight individuals 10,11,28]. Nevertheless, be-
fore extrapolating these data in a normative setting (e.g.,
WADA policy) [30], further studies in a larger popula-
tion of overweight/obese athletes are mandatory, being
the latter population different from ours, i.e., a small
cohort of obese sedentary subjects.
A limitation of the present study could be the meas-
urement of circulating levels of few GH isoforms, i.e.
uniquely 22 kDa- and 20 kDa-GH, which have similar
disappearance rates in circulation [10]. Since other
GH isoforms, such as non-22 kDa-GH, persist in the
recovery phase after acute exercise administered to
normal-weight subjects [10], future studies should in-
vestigate the post-exercise kinetics of the remaining GH
isoforms also in obese individuals. This issue is of great
interest, being some GH isoforms more hyperglycemic
than others [15] and exercise a well-recognized strategy to
improve metabolic control [31]. In this respect, we cannot
exclude that obese subjects have slower mechanisms of
clearance for some GH isoforms, other than 22 kDa- and
20 kDa-GH, particularly those of higher molecular weight
(e.g., dimers or oligomers).
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evident when comparing exercise-induced GH responses
in studies in which different analytical methods were
used. In particular, Rigamonti et al. [16] showed that
WBV evoked a significant increase in (total?) GH levels,
measured by a the commercially available immuno-
metric chemiluminescence assay Immulite 2000 (DPC,
Los Angeles, USA), while, in the present study, no sig-
nificant changes in either 22 kDa- or 20 kDa-GH were
found after WBV (alone). This might imply that some
pharmacological and physiological stimuli selectively re-
lease some GH isoforms and not others or that, more
likely, due to analytical reasons (e.g., sensitivity and spe-
cificity of the assays), GH stimulation may not be detect-
able and, erroneously, considered absent. So, before
drawing any conclusion regarding the ineffectiveness of
a GH stimulus, one should know what GH isoforms
are measured. Since, as shown by recent biochemical
and pharmacological studies [1, 2], activation of GH
receptor depends on the specificity of GH isoform(s),
measurement of (even very low) levels of any GH
isoform is fundamental to understand signal transduc-
tion at molecular level and clinical effects in the
endocrinological practice.
Finally, it is also worth mentioning that, in the
present study, there was an increasing variability of
circulating levels of GH isoforms during the recovery
phase (i.e. starting from T30). This finding, already evi-
denced by Wallace et al. [10], is likely to be related to
generation of GH fragments and/or dimers/oligomers
in circulation, which could impair the specificity of our
assays. However, despite this (potential) analytical inter-
ference, the ratio of circulating levels of 22 kDa- to 20
kDa is robustly stable.
Before closing, two other limitations should be
recalled, i.e., the reduced number of subjects re-
cruited and inclusion of only males. Therefore, the
conclusions of the present study can be considered
only preliminary; furthermore, we do propose a more
extensive use of advanced analytical methods to
measure GH isoforms in obesity and other patho-
physiological conditions for better understanding the
complexity of GH-IGF-I axis.
Conclusions
The results of the present study confirm the ability
of MVC, alone and in combination with WBV, to
stimulate both 22 kDa- and 20 kDa-GH secretion in
obese patients, being these responses related to the
exercise workload. Since the ratio of 22 kDa- to 20
kDa-GH is constant after exercise and independent
from the protocols of exercise as in normal-weight
subjects, hyposomatotropism in obesity does not seem to
depend on an unbalance of circulating GH isoforms andexercise-induced GH response is unlikely to affect the reli-
ability of direct methods for detection of rhGH abuse in
overweight/obese athletes. Since the present study was
carried out in a small cohort of obese sedentary adoles-
cents, these preliminary results should be confirmed by
further future studies enrolling overweight/obese subjects
with a wider age range.
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